Want to join the conversation?
Generic pharmaceutical products maker $LCI said it plans to co-develop a generic insulin product for the US market with its Chinese partner, YiChang HEC ChangJiang Pharmaceutical Co., an HEC Group company. $LCI has the exclusive US marketing rights to the product, which is currently in late stage development.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.